Interactions Between Cyclosporin and Lipid-Lowering Drugs

@article{sberg2012InteractionsBC,
  title={Interactions Between Cyclosporin and Lipid-Lowering Drugs},
  author={Anders Nikolai {\AA}sberg},
  journal={Drugs},
  year={2012},
  volume={63},
  pages={367-378}
}
  • A. Åsberg
  • Published 2012
  • Biology, Medicine, Chemistry
  • Drugs
Dyslipidaemia is more frequent in solid organ transplant recipients than in the general population, primarily as a result of immunosuppressive drug treatment. Both cyclosporin and corticosteroids are associated with dyslipidaemic adverse effects. In order to reduce the overall cardiovascular risk in these patients, lipid-lowering drugs have become widely used, especially HMG-CoA reductase inhibitors (statins). Cyclosporin, as well as most statins (lovastatin, simvastatin, atorvastatin and… 

Tables from this paper

[Hypolipidemic treatment under special conditions: posttransplant and/or immunosuppressive therapy].
  • M. C. Izar
  • Biology, Medicine
    Arquivos brasileiros de cardiologia
  • 2005
TLDR
Pravastatin appears to be the safest compound, once it is glucuronized, and when combined with any statin a careful monitoring of cyclosporine levels is recommended, due to a narrow therapeutic window of the immunosuppressive agent.
Treatment of dyslipidemia in kidney transplantation
TLDR
Rather than using high-dose statin in difficult patients, an association with ezetimibe is suggested, and new lipid-lowering drugs are emerging but their safety and efficacy in KT patients still need to be assessed.
ERSPECTIVES IN CLINICAL HARMACOLOGY rug interactions with lipid-lowering rugs : Mechanisms and clinical relevance
TLDR
The effects of cyclosporine and gemfibrozil explain the increased plasma statin concentrations and, together with pharmacodynamic factors, the increased risk of myotoxicity when coadministered with statins.
More Potent Lipid-Lowering Effect by Rosuvastatin Compared With Fluvastatin in Everolimus-Treated Renal Transplant Recipients
TLDR
Rosuvastatin showed a superior lipid-lowering effect compared to fluvastatin in stable RTR receiving everolimus, and seems to be as safe as theEverolimus/fluvASTatin combination.
Cytochrome P450-mediated cardiovascular drug interactions
  • A. Scheen
  • Biology, Medicine
    Expert opinion on drug metabolism & toxicology
  • 2011
TLDR
Clinicians are encouraged to develop their knowledge of CYP-mediated DDIs so that they can choose safe drug combination regimens, adjust drug dosages appropriately and conduct therapeutic drug monitoring for drugs with narrow therapeutic indices.
Metabolic Drug Interactions with Immunosuppressants
  • K. Monostory
  • Medicine, Biology
    Organ Donation and Transplantation - Current Status and Future Challenges
  • 2018
TLDR
An up-to-date summary of functional polymorphisms of enzymes involved in the metabolism of immunosuppressants with low molecular weight and of the clinical significance of metabolic drug interactions between Immunosuppressive agents and other drugs in therapeutic regimens of transplant recipients is provided.
Cyclosporin A-Induced Hyperlipidemia
TLDR
An overview of CsA-induced hyperlipidemia is given, with a focus on the data available that might explain the underlying mechanism(s) and the available treatment regimes used to treat hyper Lipidemia induced by immunosuppressant drugs are described.
The pros and the cons of mTOR inhibitors in kidney
TLDR
The main dose-dependent adverse events of mTOR inhibitors are hyperlipidemia, thrombocytopenia, mucositis, edema, and proteinuria; the use of m TOR inhibitors in renal transplantation may allow to reduce the doses of calcineurin inhibitors.
The pros and the cons of mTOR inhibitors in kidney transplantation
  • C. Ponticelli
  • Medicine, Biology
    Expert review of clinical immunology
  • 2014
TLDR
The main dose-dependent adverse events of mTOR inhibitors are hyperlipidemia, thrombocytopenia, mucositis, edema, and proteinuria; the use of m TOR inhibitors in renal transplantation may allow to reduce the doses of calcineurin inhibitors.
Statin use and incident cardiovascular events in renal transplant recipients
TLDR
The effect of statins on a compound CV endpoint, comprised of ischaemic CV events and CV mortality in RTR, is elucidated, with subgroup analysis focussing on cyclosporine users.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 72 REFERENCES
Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine.
TLDR
The broad use of fluvastatin to treat hypercholesterolemia in renal transplant recipients is supported and the significant reductions in total cholesterol and low- density lipoprotein cholesterol levels and the ratio of low-density to high-density lipoproteins achieved in these patients support the broader use of the drug.
Effects of Simvastatin and Pravastatin on Hyperlipidemia and Cyclosporin Blood Levels in Renal Transplant Recipients
TLDR
The results of this study show the efficacy and safety of hydroxymethylglutaryl coenzyme A reductase inhibitors in the treatment of hyperlipidemia in kidney transplant patients.
Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
TLDR
Pravastatin 40 mg/day for 1 week in the patient group caused a significant reduction in total cholesterol (C) and LDL-C from 8.11 +/- 1.20 mmol/l and 5.88 +/- 1-24h, respectively, and no significant increase in Cmax or AUC was found on Day 1 to Day 8.
The interaction of fluvastatin and cyclosporin A in renal transplant patients.
  • P. Li, T. Mak, K. Lai
  • Medicine, Biology
    International journal of clinical pharmacology and therapeutics
  • 1995
TLDR
Fluvastatin (20 mg daily) may be used safely without extra monitoring of blood CsA concentrations in renal transplant patients with dyslipoproteinemia despite dietary control.
Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients.
TLDR
A randomized single-blind placebo crossover study designed to determine the safety and effectiveness of simvastatin in a single daily 5-mg evening dose was conducted in 26 stable renal transplant patients, 14 of whom were receiving cyclosporin A.
Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A
TLDR
Monitoring the safety and efficacy of treatment with the HMG-CoA reductase inhibitor fluvastatin in heart transplant recipients compared to healthy controls found that treatment with these substances correlates with an increased risk for the development of rhabdomyolysis due to therapy with the immunosuppressive cyclosporine A.
Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
  • L. Renders, I. Mayer-Kadner, I. Hauser
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2001
TLDR
In the study population both statins were very effective in lowering elevated LDL cholesterol levels, and Cerivastatin did not influence CsA blood trough levels, whereas atorvastatin increased C sA levels in four of 10 patients.
Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
TLDR
It is concluded that low dose atorvastatin (10 mg/day) can be successfully used and appears to be safe in the treatment of posttransplant hyperlipidemia and its long-term effects on patient morbidity and mortality as well as graft survival should be investigated in larger and more prolonged prospective trials.
Clinical Pharmacokinetics of Fluvastatin
TLDR
Fluvastatin is relatively hydrophilic, compared with the semisynthetic HMG-CoA reductase inhibitors, and, therefore, it is extensively absorbed from the gastrointestinal tract, and does not appear to have a significant effect on other CYP isoenzymes or P-glycoprotein-mediated transport in vivo.
...
1
2
3
4
5
...